Chembio Diagnostics to Report Second Quarter 2019 Financial Results on August 6, 2019

by NASDAQ Market News July 24, 2019

NASDAQ Market News
Click here to email author

Study Published in American Health Drug Benefits Suggests that Non-Invasive Screening Methods, Including Epi proColon®, Could Be A Cost-Effective Option To Help Achieve Target U.S. Colorectal Cancer Screening Rates

Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia

Ads